Irritable Bowel Syndrome Drug Development - 2018 Pipeline Analysis - ResearchAndMarkets.com

DUBLIN--()--The "2018 Irritable Bowel Syndrome Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.

Irritable bowel syndrome (IBS) is a chronic gastrointestinal and functional bowel disorder that affects around 10-15% of population during their lifetime. The drug market for this disease is estimated to be around $1.5 billion.

Over 50 companies and universities are focusing on developing treatment options for Irritable Bowel Syndrome.

This report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Irritable Bowel Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Irritable Bowel Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Companies Mentioned

  • 4D Pharma PLC
  • Alfa Wassermann SpA
  • Allergan
  • Aptevo Therapeutics Inc
  • Ardelyx Inc
  • Assembly Biosciences
  • Astellas Pharma Inc
  • Axim Biotechnologies
  • CinRx Pharma LLC
  • ConSynance Therapeutics
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co
  • Enterome Bioscience SA
  • GlaxoSmithKline
  • ImmuneBiotech AB
  • Innovative Med Concepts LLC
  • Ironwood Pharmaceuticals
  • LTT Bio-Pharma Co
  • Napo Pharmaceuticals
  • Nobilis Therapeutics
  • Orphomed Inc
  • Outpost Medicine
  • Palo BioFarma SL
  • Pfizer Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma
  • Scythian Biosciences Corp
  • Seldar Pharma Inc
  • SK Biopharmaceuticals
  • Sumitomo Dainippon Pharma
  • Synergy Pharmaceuticals
  • Synthetic Biologics Inc
  • Tillotts Pharma
  • Velicept Therapeutics Inc
  • Vitality Biopharma

Key Topics Covered

1 Table of Contents

2 Irritable Bowel Syndrome Pipeline Analysis

3 Irritable Bowel Syndrome - Company-wise Pipeline Analysis

4 Irritable Bowel Syndrome R&D Pipeline Snapshots

5 Recent Developments in Irritable Bowel Syndrome Pipeline

For more information about this report visit https://www.researchandmarkets.com/research/qvdr7c/irritable_bowel?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Gastrointestinal Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Gastrointestinal Drugs